Table 2.
Author (Case No) |
K+ Dose (mEq/L) |
RoA | AM K+ cc (mEq/L) |
Survived (Yes/No) |
---|---|---|---|---|
Watanabe (a) [6] | 55 | IV | N/A | No |
Watanabe (b) [6] | IV | N/A | No | |
Wetherton (a) [5] | 40 | IV | N/A | No |
Wetherton (b) [5] | 26.4 | IV | N/A | No |
Wetherton (c) [5] | N/A | IV | 12.4 | No |
Chaturwedi [16] | 14.68 | IV | N/A | No |
Restuccio [8] | 283 | oral | 9.6 | No |
Saxena [9] | 800 | oral SR | 9.6 | No |
Kaplan [11] | 540–720 | oral | N/A | No |
Wetli (a) [17] | N/A | oral SR | 10.1 | No |
Wetli (b) [17] | N/A | N/A | 10.8 | No |
Horisberger [18] | N/A | N/A | 17.7 | Yes |
Su (a) [19] | 1000 | oral SR | 9.7 | Yes |
Illingworth (a) [20] | 168 | oral SR | 9.1 | Yes |
Illingworth (b) [20] | 320 | oral SR | 9.3 | Yes |
Illingworth (c) [20] | oral SR | 8.9 | Yes | |
Steedman [21] | 480 | oral SR | 9.1 | Yes |
Höjer [22] | 1000 | oral SR | 9.2 | Yes |
Bosse [23] | oral SR | 11 | Yes | |
Nilsson [24] | 300 | oral SR | 10.3 | Yes |
Iijama [25] | 240 | oral SR | 7.0 | Yes |
Madan (a) [26] | 239 | oral 1 | 9.4 | Yes |
Madan (b) [26] | 1237 | oral 1 | 9 | Yes |
Madan (c) [26] | 798 | oral 1 | 8.4 | Yes |
Madan (d) [26] | 1601 | oral 1 | 8.2 | Yes |
1 not specified, RoA: Route of administration, IV: intravenous, SR: slow-release, AM: ante-mortem, N/A: no data available.